ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ELUT / insiders
PTHS (20) EXOZ (32) INMB (30) CRBU (32) ⌘ Pro Terminal →

Elutia Inc. (Class A) (ELUT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$0.82 -1.92% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.82

Elutia Inc. (Class A) (ELUT) receives a Roarable Rating of E (Strong Sell) and flashes a Red SELL / AVOID rating (31/100 RQD Confidence). Alongside weak composite pillar scores, our SEC filing scanner spotted paper earnings outpacing operating cash flow (+296.7% (NI vs OCF)).

ROARABLE E • RED ALERT Cap $37.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ELUT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ELUT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Elutia Inc. (Class A) (NASDAQ: ELUT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.82 (-1.92% 1D, market cap $37.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 7/20. Active quantitative signal ACCOUNTING_MIRAGE (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ELUT compare to PTHS and EXOZ in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ELUT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 53.7%, and ROIC of -35.0%. By comparison, PTHS (Pelthos Therapeutics Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $36.0M) and EXOZ (eXoZymes Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $38.4M). Among the 5-stock peer group, ELUT leads on earnings multiple (N/A) while ELUT leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ELUT?
▼

Per ELUT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001708527), Elutia Inc. (Class A) generated $12.3M in revenue (-15.0% YoY), $53.4M in net income, and -$46.7M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.82 (-0.54%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (3)Whales (10)SEC (7)Macro (7)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-12.2% Base Target
$1 Bull$1 Base$1 Bear
📬 FREE ELUT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ELUT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY ELUT SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (32% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (23% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
23
Grade E$0.77+5.2% Next Q
Q2 (-2Q)
26
Grade E$0.81+0% Next Q
Q3 (-1Q)
28
Grade E$0.81+1.2% Next Q
Current
31
Grade E$0.82-9.4% Hist 90D α
Trajectory: E (23) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ELUT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ELUT currently carries a cautious 31/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.83) and Max Pain ($0.86) forces dealer call-delta covering toward $1.45.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELUT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ELUT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ELUT Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ELUT)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ELUT. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELUT)

  • ✓Walkthrough of ELUT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ELUT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.81%⚡ TESTING RESISTANCE
2026-11-03O $0.82H $0.84L $0.82C $0.82VOL 138.3K
RES: $0.87SUP: $0.61SMA50: $0.83SMA200: $0.97
$1.32$1.15$0.97$0.79$0.62RES $0.87SUP $0.61$0.822026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ELUT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ELUT Butterfly Map → + Track ELUT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -15.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ELUT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ELUT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ELUT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELUT)

Health Care Rank #771 of 1015 ⚔️ PTHS vs ELUT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ELUT vs. PTHS, EXOZ, INMB, CRBU)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Elutia Inc. (Class A) (ELUT) ranks #771 by composite RQD confidence (31/100, grade E) and #776 by equity capitalization ($37.1M). Within this direct 5-issuer industry benchmark cohort, ELUT leads on earnings valuation at N/A trailing P/E, while ELUT leads on capital efficiency and profitability with -35.0% ROIC and 53.7% gross margin. EXOZ currently holds the highest overall quantitative score in the immediate peer group at 32/100 (E) compared with ELUT at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ELUT ACTIVE
Elutia Inc. (Class A)
E 31/100 — 53.7% -35.0% -1.92% $37.1M Benchmark Subject
PTHS
Pelthos Therapeutics Inc.
E 20/100 — 76.3% -35.0% +22.55% $36.0M /pths-vs-elut →
EXOZ
eXoZymes Inc.
E 32/100 — — -35.0% +9.44% $38.4M /exoz-vs-elut →
INMB
INmune Bio Inc.
E 30/100 — — -35.0% -4.83% $44.9M /inmb-vs-elut →
CRBU
Caribou Biosciences Inc.
E 32/100 — — -35.0% +3.95% $45.4M /crbu-vs-elut →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001708527 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Elutia Inc. (Class A) (ELUT) reported GAAP revenue of $12.3M (-15.0% vs. FY2024 revenue of $14.5M , and -85.6% cumulative change since FY2023) , GAAP net income of $53.4M, operating cash flow of -$44.8M, and free cash flow of -$46.7M (-100.3% YoY). On the balance sheet, ELUT closed FY2025 with $62.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $12.3M $53.4M -$44.8M -$46.7M $62.4M —
FY2024 (FY) 2024-12-31 $14.5M -$53.9M -$22.7M -$23.3M $36.1M $22.6M
FY2023 (FY) 2023-12-31 $85.5M -$37.7M -$21.8M -$21.8M — —

3. ELUT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ELUT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Elutia Inc. (Class A) (NASDAQ: ELUT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.82 (-1.92% 1D, market cap $37.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 7/20. Active quantitative signal ACCOUNTING_MIRAGE (BEARISH, conviction undefined/100) notes: undefined.

How does ELUT compare to PTHS and EXOZ in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ELUT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 53.7%, and ROIC of -35.0%. By comparison, PTHS (Pelthos Therapeutics Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $36.0M) and EXOZ (eXoZymes Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $38.4M). Among the 5-stock peer group, ELUT leads on earnings multiple (N/A) while ELUT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ELUT?

Per ELUT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001708527), Elutia Inc. (Class A) generated $12.3M in revenue (-15.0% YoY), $53.4M in net income, and -$46.7M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ELUT trading relative to its 50-day, 200-day, and 52-week technical levels?

ELUT last traded at $0.82 (-1.92% on volume of 34,652 shares), positioning the stock -1.20% below its 50-day simple moving average ($0.83) and -15.46% below its 200-day simple moving average ($0.97). Across its 52-week range of $0.50 to $1.38, ELUT sits at the 36.4% percentile with a 14-day RSI of 53.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.92).

Direct Sub-Reports: ELUT RQD Cockpit ELUT 12M Forecast ELUT Earnings & Move ELUT Dividends & DRIP ELUT Insiders & 13F ELUT Whale Options ELUT Profit Sankey ELUT News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

ELUT — Elutia Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Elutia Inc. (Class A) (ELUT) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.82 (-1.92% 1D, market capitalization $37.1M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 53.7%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Elutia Inc. (Class A) (ELUT) is a NASDAQ-listed issuer...0B, which conflicts with the $36.0M shown in market data; the profile figure is rounded to zero billions. — for product or customer detail.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Elutia Inc. (Class A) (ELUT) reported $12.3M in annual revenue (up from $14.5M in FY2024, -15.0% YoY) and $53.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($85.5M revenue, -$37.7M net income) through FY2025, ELUT scaled operating cash flow to -$44.8M and free cash flow to -$46.7M, backed by $62.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 10/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $0.50 – $1.38 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are therefore — The sector correlation is limited to Health Care / Biological Products. The primary 2nd-order risk the source identifies is the accrual gap: if working-capital build reverses, reported earnings could be pressured. Investors should watch the Q3 2026 release for cash realization against reported income.

  • Key Question #1: Can ELUT sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $12.3M and free cash flow of -$46.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ELUT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ELUT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Elutia Inc. (Class A) (ELUT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ELUT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ELUT Bull vs. Bear Conversation Board — What's Your Call at $0.82?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ELUT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ELUT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $0.99 (+17.9%)
📌 Pinned Debate

FY 2025 reported net income of $53.4M, well above its -$26.9M operating income, and the stock trades at a $36.0M market cap against $36

Here is why I am bullish on ELUT here at $0.84: FY 2025 reported net income of $53.4M, well above its -$26.9M operating income, and the stock trades at a $36.0M market cap against $36.4M in cash.. Compare ELUT's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $0.80 are getting bought.

ArenaChamp_24 🐂 BULL

@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (53.7%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $0.72 (-14.3%)
Spot @ $0.84

Operating income and free cash flow were negative in every reported period, the Butterfly Graph flags a 92-severity bearish accrual gap

Operating income and free cash flow were negative in every reported period, the Butterfly Graph flags a 92-severity bearish accrual gap, and the Altman Z-Score is 0.2.. Look at the math on ELUT: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $0.74 before getting long.

LIVE TAPE